Description

Pramipexol-ZN (pramipexole) tablets 0.25 mg. № 30

Ingredients

Active ingredient: Pramipexole dihydrochloride monohydrate.
Other ingredients: Lactose monohydrate, maize starch, colloidal anhydrous silica, magnesium stearate.

Dosage

Recommended dosage: The usual starting dose is 0.125 mg taken once daily 2-3 hours before bedtime. The dose may be increased gradually based on individual response and tolerability.

Indications

Pramipexol-ZN tablets are indicated for the treatment of Parkinson’s disease and restless legs syndrome (RLS).

Contraindications

Do not use Pramipexol-ZN tablets if you have a known hypersensitivity to pramipexole or any of the other ingredients in the tablet.

Directions

Take Pramipexol-ZN tablets orally with or without food. Do not crush or chew the tablets. Follow the dosage instructions provided by your healthcare provider.

Scientific Evidence

Studies have shown that pramipexole, the active ingredient in Pramipexol-ZN tablets, is effective in improving motor symptoms in patients with Parkinson’s disease. Research published in the Journal of Neurology indicates that pramipexole has a favorable efficacy and safety profile in the management of restless legs syndrome.

Additional Information

It is important to note that Pramipexol-ZN tablets may cause dizziness or drowsiness. Avoid driving or operating machinery until you know how this medication affects you. Consult your doctor if you experience any unusual side effects while taking this medication.

Pharmacological Effects

Pramipexole is a non-ergot dopamine agonist that works by stimulating dopamine receptors in the brain. By mimicking the action of dopamine, pramipexole helps to improve motor function in Parkinson’s disease and alleviate symptoms of restless legs syndrome.

Clinical Trials and Comparative Effectiveness

Clinical trials have demonstrated the efficacy of pramipexole in improving motor symptoms and quality of life in patients with Parkinson’s disease. Compared to other dopamine agonists, pramipexole has shown similar efficacy but with a lower risk of causing dyskinesias.

Overall, Pramipexol-ZN tablets offer a well-established treatment option for Parkinson’s disease and restless legs syndrome, supported by scientific evidence and clinical trials.